Centenial Surgical Suture Ltd
Incorporated in 1995, Centenial Surgical Suture Ltd is engaged in manufacturing of surgical sutures & other medical devices.
- Market Cap ₹ 47.3 Cr.
- Current Price ₹ 130
- High / Low ₹ 160 / 84.0
- Stock P/E 45.4
- Book Value ₹ 88.3
- Dividend Yield 0.00 %
- ROCE 8.07 %
- ROE 3.57 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -1.80% over past five years.
- Company has a low return on equity of 2.88% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
54.00 | 50.96 | 51.71 | 51.39 | 52.84 | 52.73 | 56.05 | 55.61 | 36.93 | 44.43 | 52.66 | 51.19 | 51.27 | |
49.15 | 46.39 | 46.47 | 46.71 | 47.95 | 48.26 | 50.64 | 49.68 | 31.82 | 39.94 | 48.26 | 46.04 | 45.71 | |
Operating Profit | 4.85 | 4.57 | 5.24 | 4.68 | 4.89 | 4.47 | 5.41 | 5.93 | 5.11 | 4.49 | 4.40 | 5.15 | 5.56 |
OPM % | 8.98% | 8.97% | 10.13% | 9.11% | 9.25% | 8.48% | 9.65% | 10.66% | 13.84% | 10.11% | 8.36% | 10.06% | 10.84% |
0.02 | 0.04 | 0.10 | 0.02 | 0.01 | 0.05 | 0.02 | 0.09 | 0.09 | 0.04 | 0.13 | 0.13 | 0.11 | |
Interest | 1.70 | 1.31 | 1.61 | 1.65 | 1.77 | 1.51 | 1.89 | 2.31 | 2.12 | 1.93 | 1.77 | 2.62 | 2.51 |
Depreciation | 0.58 | 0.59 | 0.83 | 0.68 | 0.59 | 0.60 | 0.69 | 1.55 | 1.55 | 1.53 | 1.30 | 1.39 | 1.88 |
Profit before tax | 2.59 | 2.71 | 2.90 | 2.37 | 2.54 | 2.41 | 2.85 | 2.16 | 1.53 | 1.07 | 1.46 | 1.27 | 1.28 |
Tax % | 39.38% | 33.95% | 34.14% | 34.18% | 32.68% | 36.10% | 29.12% | 39.81% | 37.25% | 42.06% | 39.73% | 11.02% | |
1.57 | 1.79 | 1.92 | 1.56 | 1.72 | 1.54 | 2.02 | 1.30 | 0.96 | 0.63 | 0.89 | 1.13 | 1.04 | |
EPS in Rs | 4.30 | 4.91 | 5.26 | 4.28 | 4.71 | 4.22 | 5.54 | 3.56 | 2.63 | 1.73 | 2.44 | 3.10 | 2.85 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 0% |
5 Years: | -2% |
3 Years: | 12% |
TTM: | -3% |
Compounded Profit Growth | |
---|---|
10 Years: | -5% |
5 Years: | -11% |
3 Years: | 6% |
TTM: | 3% |
Stock Price CAGR | |
---|---|
10 Years: | 13% |
5 Years: | 25% |
3 Years: | 33% |
1 Year: | 8% |
Return on Equity | |
---|---|
10 Years: | 5% |
5 Years: | 3% |
3 Years: | 3% |
Last Year: | 4% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 |
Reserves | 12.04 | 13.83 | 15.79 | 17.35 | 19.07 | 20.62 | 22.63 | 23.18 | 24.15 | 24.77 | 25.66 | 26.79 |
12.65 | 11.32 | 12.28 | 13.11 | 15.24 | 14.37 | 13.10 | 12.72 | 13.47 | 9.30 | 9.92 | 23.24 | |
17.63 | 19.53 | 21.80 | 16.68 | 16.07 | 14.89 | 15.61 | 27.96 | 27.00 | 21.85 | 25.40 | 23.70 | |
Total Liabilities | 47.74 | 50.10 | 55.29 | 52.56 | 55.80 | 55.30 | 56.76 | 69.28 | 70.04 | 61.34 | 66.40 | 79.15 |
4.72 | 4.53 | 4.13 | 3.64 | 3.71 | 3.80 | 4.08 | 10.44 | 8.97 | 7.60 | 6.46 | 12.77 | |
CWIP | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.22 | 0.22 | 0.22 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
42.83 | 45.38 | 50.97 | 48.73 | 51.90 | 51.28 | 52.46 | 58.62 | 61.07 | 53.74 | 59.94 | 66.38 | |
Total Assets | 47.74 | 50.10 | 55.29 | 52.56 | 55.80 | 55.30 | 56.76 | 69.28 | 70.04 | 61.34 | 66.40 | 79.15 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.63 | -0.25 | 0.21 | -1.51 | 0.00 | 1.76 | 1.55 | 2.08 | 1.97 | 4.75 | 1.30 | 6.21 | |
-0.53 | -0.42 | -0.36 | -0.19 | -2.38 | -0.64 | -1.02 | -1.31 | -0.89 | -0.17 | -0.18 | -7.92 | |
2.24 | -1.34 | 0.96 | 0.82 | 2.14 | -0.88 | -1.27 | -0.37 | -1.27 | -4.87 | -1.05 | 2.06 | |
Net Cash Flow | 2.34 | -2.01 | 0.80 | -0.88 | -0.25 | 0.24 | -0.75 | 0.40 | -0.18 | -0.28 | 0.07 | 0.35 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 127.89 | 135.08 | 138.21 | 132.75 | 130.76 | 125.29 | 134.80 | 153.26 | 221.39 | 160.44 | 142.71 | 134.05 |
Inventory Days | 218.51 | 297.67 | 350.07 | 365.93 | 468.59 | 465.89 | 434.68 | 483.86 | 1,276.44 | 599.23 | 677.26 | 909.72 |
Days Payable | 144.77 | 162.36 | 167.34 | 124.26 | 146.28 | 135.64 | 120.26 | 187.98 | 372.75 | 159.00 | 222.42 | 207.75 |
Cash Conversion Cycle | 201.63 | 270.39 | 320.94 | 374.42 | 453.06 | 455.54 | 449.22 | 449.14 | 1,125.08 | 600.67 | 597.56 | 836.02 |
Working Capital Days | 159.45 | 187.94 | 205.48 | 233.39 | 156.25 | 164.05 | 167.69 | 172.36 | 403.64 | 313.08 | 276.49 | 329.63 |
ROCE % | 15.21% | 13.25% | 14.08% | 11.59% | 11.40% | 9.78% | 11.62% | 10.84% | 8.65% | 7.27% | 8.03% | 8.07% |
Documents
Announcements
- Closure of Trading Window 1d
-
Price Of The Scrip Of Our Company Has Seen An Abnormal Price Rise, Which Was Not Supported By Any Corporate Announcements Or Material Changes In The Business Activities Of Our Company And Manipulative Trade Observed In Our Scrip And Request Urgent Attention For Possible MISUSE / UNETHICAL / UNUSUAL TRADES In Our Company Scrip.
11 Sep - Company reports unusual trading and price manipulation.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 4 Sep
- Reg. 34 (1) Annual Report. 3 Sep
- Announcement under Regulation 30 (LODR)-Newspaper Publication 30 Aug
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio:
Company manufactures highly specialized absorbable and non-absorbable sutures (cardio vascular sutures and atraumatic needled sutures) that are primarily used in CABG surgeries, and other medical devices. It sells products under:
a) Absorbable Sutures:[1]
Consists of Natural Sutures with brand names like Centenial -Catgut Plain and Centenial-Catgut Chromic in addition to Synthetic Sutures, with brand names like Centicryl, Monosynth and Centisorb
b) Non Absorbable Sutures:[2]
Brand names like Centilene, Centlon Centisilk, Centlinen, Centibond, Centsteel, Centidene
c) Medical Devices:[3]
T-suit, Centilene Mesh, Skin Stapler, Centiclip, Aortic Punch and KNIFE which is a Cardiovascular Vessel Knife